Navigation Links
China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Date:9/2/2008

HARBIN, China, Sept. 2 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (AMEX: CSY), a leading fully integrated pharmaceutical company producing external use, over-the-counter drugs in the People's Republic of China ("PRC"), today announced that it has received approval to list its common stock on the NASDAQ Global Market.

China Sky One expects to start trading on the NASDAQ Global Market on September 15, 2008, and that the last day of trading on the American Stock Exchange ("AMEX") will be September 12, 2008. The trading symbol for China Sky One's common stock on the NASDAQ Global Market will be "CSKI". The Company primarily sells its products in the People's Republic of China (PRC).

"We are very excited to list on NASDAQ and consider the change to be a significant milestone in China Sky One's development as a U.S. public company," commented Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One. "We are confident that the listing on NASDAQ will allow us to further enlarge our investor base and increase both our liquidity and visibility in the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit

SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
2. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
3. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
4. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
5. China Kangtai Cactus Biotech Announces Record Second Quarter Results
6. China Biologic Products Reports Second Quarter 2008 Results
7. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
8. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
9. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
10. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
11. China Medicine Announces Strong Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that ... has added two more  consultants to its team ... PPL-003 uses a new proprietary cell permeable peptide ... its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... , September 23, 2014 ... Closed System Transfer     Devices  (CSTD) ... partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading ... Taiwan , China ... the company continues to expand globally, and throughout ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... from around the globe will convene at ... International Conference, to be held October 26-28 ... in evidence-based research and practice in individualized ... physicians, scientists, researchers, nurses, psychologists, nutritionists, naturopaths, ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... of seven institutions in the country selected by ... this year,s BEST Award a $2 million ... most promising biomedical sciences graduate trainees to career ... they have traditionally taken. , The award funds ... Biomedical Scientists (iJOBs) program. It includes courses, seminars, ...
Breaking Biology News(10 mins):Plant variants point the way to improved biofuel production 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... relatively common to come across petrol stations surrounded by houses, ... (UM) have studied the effects of contamination at petrol stations ... in buildings less than 100 metres from the service stations. ... increases the risk of cancer have been recorded at ...
... has been awarded a $2.3 million grant by the ... focusing on developing a novel stem cell based therapy ... studying human induced pluripotent stem (iPS) cells derived from ... in the lab and investigate the role of inflammation ...
... not-so-distant evolutionary past, stress often meant imminent danger, ... of our body,s stress response is to stock-pile ... Unit (MMPU), a collaboration between the European Molecular ... University of Heidelberg Medical Centre, have discovered how ...
Cached Biology News:Petrol stations pollute their immediate surroundings 2Stem cell leader awarded $2.3 million grant for Parkinson's 2Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Permeabilization Solution, 5X...
Biology Products: